Published online before print December 28, 2007, doi: 10.1161/CIRCULATIONAHA.107.743872
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:1642-1648.)
© 2008 American Heart Association, Inc.
Coronary Heart Disease |
Fractalkine Deficiency Markedly Reduces Macrophage Accumulation and Atherosclerotic Lesion Formation in CCR2–/– Mice
Evidence for Independent Chemokine Functions in Atherogenesis
From the Gladstone Institute of Cardiovascular Disease (N.S., L.C., I.F.C.), San Francisco, Calif; Immunobiology Institute (S.A.L.), Mount Sinai School of Medicine, New York, NY; and Cardiovascular Research Institute (I.F.C.), Department of Medicine, University of California, San Francisco, Calif.
Correspondence to Israel F. Charo, MD, PhD, Gladstone Institute of Cardiovascular Disease, 1650 Owens St, San Francisco, CA, 94158. E-mail icharo{at}gladstone.ucsf.edu
Received October 3, 2007; accepted October 31, 2007.
Background— Monocyte-derived foam cells are the hallmark of early atherosclerosis, and recent evidence indicates that chemokines play important roles in directing monocyte migration from the blood to the vessel wall. Genetic deletions of monocyte chemoattractant protein-1 (MCP-1, CCL2), fractalkine (CX3CL1), or their cognate receptors, CCR2 and CX3CR1, markedly reduce atherosclerotic lesion size in murine models of atherosclerosis. The aim of this study was to determine whether these 2 chemokines act independently or redundantly in promoting atherogenesis.
Methods and Results— We crossed CX3CL1–/–ApoE–/– and CCR2–/–ApoE–/– mice to create CX3CL1–/–CCR2–/–ApoE–/– triple knockouts and performed a 4-arm atherosclerosis study. Here, we report that deletion of CX3CL1 in CCR2–/– mice dramatically reduced macrophage accumulation in the artery wall and the subsequent development of atherosclerosis. Deletion of CX3CL1 did not reduce the number of circulating monocytes in either "wild-type" ApoE–/– mice or CCR2–/–ApoE–/– mice, which suggests a role for CX3CL1 in the direct recruitment and/or capture of CCR2-deficient monocytes.
Conclusions— These data provide the first in vivo evidence for independent roles for CCR2 and CX3CL1 in macrophage accumulation and atherosclerotic lesion formation and suggest that successful therapeutic strategies may need to target multiple chemokines or chemokine receptors.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  E. L. Gautier, C. Jakubzick, and G. J. Randolph Regulation of the Migration and Survival of Monocyte Subsets by Chemokine Receptors and Its Relevance to Atherosclerosis Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1412 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K. Swirski, R. Weissleder, and M. J. Pittet Heterogeneous In Vivo Behavior of Monocyte Subsets in Atherosclerosis Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1424 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kang, S.-P. Lee, K. E. Kim, H.-Z. Kim, S. Memet, and G. Y. Koh Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages Blood, March 12, 2009; 113(11): 2605 - 2613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mosig, K. Rennert, S. Krause, J. Kzhyshkowska, K. Neunubel, R. Heller, and H. Funke Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+CD16+ monocytes in detoxification of oxidized LDL FASEB J, March 1, 2009; 23(3): 866 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. White and D. R. Greaves Fractalkine: one chemokine, many functions Blood, January 22, 2009; 113(4): 767 - 768. [Full Text] [PDF]
|
|
|
|
|
|
L. Landsman, L. Bar-On, A. Zernecke, K.-W. Kim, R. Krauthgamer, E. Shagdarsuren, S. A. Lira, I. L. Weissman, C. Weber, and S. Jung CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival Blood, January 22, 2009; 113(4): 963 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zernecke, E. Shagdarsuren, and C. Weber Chemokines in Atherosclerosis: An Update Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1897 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Aukrust, B. Halvorsen, A. Yndestad, T. Ueland, E. Oie, K. Otterdal, L. Gullestad, and J. K. Damas Chemokines and Cardiovascular Risk Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1909 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schober Chemokines in Vascular Dysfunction and Remodeling Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Engel, J. Maurer, A. P. Tittel, C. Weisheit, T. Cavlar, B. Schumak, A. Limmer, N. van Rooijen, C. Trautwein, F. Tacke, et al. CCR2 Mediates Homeostatic and Inflammatory Release of Gr1high Monocytes from the Bone Marrow, but Is Dispensable for Bladder Infiltration in Bacterial Urinary Tract Infection J. Immunol., October 15, 2008; 181(8): 5579 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Popovic, Y. Laumonnier, L. Burysek, T. Syrovets, and T. Simmet Thrombin-induced expression of endothelial CX3CL1 potentiates monocyte CCL2 production and transendothelial migration J. Leukoc. Biol., July 1, 2008; 84(1): 215 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Combadiere, S. Potteaux, M. Rodero, T. Simon, A. Pezard, B. Esposito, R. Merval, A. Proudfoot, A. Tedgui, and Z. Mallat Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice Circulation, April 1, 2008; 117(13): 1649 - 1657. [Abstract] [Full Text] [PDF]
|
|